ABA Editorial · Jul 30, 2025 · 14 min read
African pharmacy retail has been one of the most visible healthtech sub-categories, with operators including mPharma, MYDAWA, Kasha, Yodawy, and Remedial Health raising substantial funding. Kasha's USD 21 million Series B was the largest ever investment in a woman-led African healthtech company. Online pharmacy captured 38 percent of African healthtech funding in 2023. This report maps the pharmacy distribution landscape.
African pharmacy distribution and retail has been one of the most heavily-funded sub-categories within African healthtech over the last five years. The business logic is clear. Pharmacies are the most common point of contact between African patients and formal healthcare systems, often substituting for general practice consultations in countries where physician access is limited. Drug prices vary significantly across retail outlets due to fragmented wholesale markets and inconsistent inventory management. Counterfeiting remains a persistent concern that undermines patient trust in formal channels. And customers increasingly expect digital interfaces for ordering, consultation, and delivery, particularly in urban centers where smartphone penetration supports e-commerce broadly. Operators including mPharma, MYDAWA, Kasha, Yodawy, and Remedial Health have built businesses addressing these conditions, and the category captured approximately 38 percent of all African healthtech funding in 2023 according to sector analysis. This report maps the pharmacy distribution and retail landscape.
mPharma is the highest-profile African pharmacy-focused operator, founded in Ghana and expanding across Nigeria, Zambia, Zimbabwe, and several other markets. The company originally built its business around negotiating with pharmaceutical companies to obtain lower medication prices and passing the savings on to patients, combined with a prescription drug inventory management system that helped partner pharmacies ensure medicine availability. mPharma has raised approximately USD 17 million in cumulative funding across multiple rounds.
Through 2023 and 2024, mPharma restructured its operations around partnerships with existing pharmacies and hospitals rather than continuing the multi-country direct operations model that had defined its earlier growth phase. The restructuring reflected the broader African healthtech pivot from growth-at-all-costs to sustainability, and specifically the recognition that running pharmacy operations directly across multiple countries imposed operational complexity that the unit economics could not comfortably support. The partnership model allows mPharma to leverage its inventory management technology and price negotiation relationships without the cost structure of direct retail operations.
MYDAWA, launched in Kenya in 2016, has pursued a different model. The company built online pharmacy operations that included booking for consultations and diagnostics, then expanded into physical pharmacy operations through acquisition. In a notable 2024 transaction, MYDAWA acquired Guardian Health, a retail pharmacy chain with more than 10 outlets across Uganda, kickstarting the company's regional expansion and business model diversification. The acquisition followed a USD 20 million investment from Alta Semper Capital.
The MYDAWA trajectory illustrates an alternative path in African pharmacy: starting online, accumulating customer and operational capability, then moving offline through acquisition rather than greenfield expansion. Acquisition can be faster and less risky than building new retail operations, though it requires access to acquisition-grade capital and target companies willing to sell at reasonable valuations. The broader pattern (between 2019 and 2022, mPharma also acquired pharmacy chains in Kenya, Uganda, and Nigeria) suggests that online-to-offline consolidation is one of the distinctive operational features of the African pharmacy sub-category.
Kasha, headquartered in Rwanda and operating across East Africa, has built a distinctive position as a women-focused healthtech platform offering confidential purchase of personal care products, reproductive health products, and other items that female consumers may prefer to buy privately. Kasha's USD 21 million Series B funding round, announced in 2022, was the largest ever investment in a woman-led African health startup, and Kasha has since continued scaling across additional markets.
The Kasha model addresses specific structural problems in African pharmacy: stigma around certain categories of products (reproductive health, hygiene, mental health medications), uneven availability in traditional pharmacy channels, and variable pricing across outlets. By offering confidential purchase and delivery, Kasha captures demand that traditional pharmacy formats may not serve well. The company's broader impact has been to demonstrate that women-led and women-focused healthtech operators can raise significant capital and build operational scale in a sector that has historically been dominated by different target demographics.
Remedial Health, operating primarily in Nigeria, focuses on the pharmacy distribution layer rather than direct retail. The company connects pharmacy retailers to verified pharmaceutical suppliers, providing inventory management, credit facilities, and logistics support. The distribution focus addresses a specific pain point in the Nigerian pharmaceutical ecosystem, where retail pharmacies often struggle to source quality medicines at reliable prices and counterfeiting has been a persistent concern.
The distribution model has the advantage of operating B2B rather than B2C, which typically produces more durable unit economics than direct-to-consumer operations. A pharmacy retailer is a repeat business customer with predictable ordering patterns, whereas individual consumers are transactional and expensive to acquire. Remedial Health was one of the five African healthtech operators that captured 59 percent of all sector funding in 2023 alongside Helium Health, Kasha, MYDAWA, and Yodawy.
Yodawy, headquartered in Egypt, has built a digital pharmacy operation serving the Egyptian market with partnerships extending into adjacent Middle Eastern and North African markets. The company raised a Series B round in 2023 that contributed to online pharmacy capturing the majority of African healthtech funding that year. The Egyptian market is the largest single pharmacy market in Africa by revenue, making it an attractive target for operators with adequate operational capability.
Counterfeit and substandard medicines are a persistent structural problem in African pharmacy. Studies across multiple African countries have documented significant shares of medicines sold through informal channels as counterfeit or substandard, with consequences ranging from ineffective treatment to patient harm. Formal pharmacy operators who invest in verified supply chains and quality assurance have the opportunity to position themselves as safer alternatives to informal channels, but only if end customers can distinguish between formal and informal operators reliably.
Digital pharmacy platforms have the specific advantage of being able to demonstrate supply chain provenance through their technology systems, but this advantage is only valuable if customers value it and are willing to pay the premium that formal operations require. In markets where patient purchasing decisions are driven primarily by price, the counterfeit alternative's cost advantage can undermine formal operators regardless of the quality difference.
Three indicators will shape African pharmacy distribution and retail. First, whether mPharma's partnership restructuring produces durable unit economics that would validate the pivot for other operators considering similar moves. Second, whether additional consolidation occurs through operators acquiring existing pharmacy chains to combine with online platforms, extending the MYDAWA-Guardian Health pattern. Third, whether the regulatory environment in key markets continues to support formal digital pharmacy operations, or whether changes in licensing or enforcement create new obstacles. African pharmacy is one of the most commercially active sub-categories of African healthtech, and its evolution will shape how African patients access medicines over the coming decade.